$NVS News

Novartis Presents Published Phase III REPLENISH Data In New England Journal Of Medicine Showing Cosentyx Achieves Statistically Significant Sustained Remission And Steroid Sparing In Polymyalgia Rheumatica With No New Safety Signals

Novartis Announces Pluvicto's New Data From PSMAddition Shows Enhanced Prostate-Specific Antigen Responses; Risk Of Prostate-Specific Antigen Lowered By 58%

Novartis shares are trading lower after the company reported worse-than-expected Q1 financial results.

Novartis CEO Flags Risks From Trump's MFN Drug Policy As Q1 Earnings Miss Estimates

Novartis Reaffirms FY2026 Outlook; Net Sales to Grow Low Single-Digit, Core Operating Income to Decline Low Single-Digit

Novartis Q1 Adj. EPS $1.99 Misses $2.13 Estimate, Sales $13.113B Miss $13.648B Estimate

The Committee for Medicinal Products for Human Use of the European Medicines Agency Backs Approval of Novartis' Itvisma For Children 2 Years And Older With 5q Spinal Muscular Atrophy

Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMs

Big Pharma Deepens AI Ties. What It Means For Novo, Novartis.

Anthropic adds Novartis CEO Vas Narasimhan to its board

Is It Too Late To Consider Sandoz Group (SWX:SDZ) After A 108% One-Year Rally?

3 Low-Volatility ETFs for Peace of Mind in Turbulent Times

Health Care Roundup: Market Talk

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors

Novartis Fabhalta Data Sharpens IgA Nephropathy Outlook And Valuation Case

Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE‑IgAN Study

Novartis Excellergy Deal Highlights Push Into Allergy Biologics And Returns

Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline

Morgan Stanley Maintains Overweight on Novartis, Raises Price Target to $170